抗真菌药物的治疗药物监测（TDM）：英国医学真菌学会指南
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
作者信息
Ashbee H Ruth, Barnes Rosemary A, Johnson Elizabeth M, Richardson Malcolm D, Gorton Rebecca, Hope William W
机构信息
Mycology Reference Centre, Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK.
出版信息
J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.
Abstract
The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.
摘要
与医学上重要的真菌病原体相关的人类疾病负担相当大。对抗真菌药理学以及抗真菌药代动力学 - 药效学的深入理解，使得治疗药物监测（TDM）成为某些抗真菌药物常规给药的重要辅助手段。TDM 可能会增加治疗成功的概率，预防药物相关毒性，并有可能防止抗真菌药物耐药性的出现。支持 TDM 的许多证据都是间接的。本文献回顾了现有文献，并为抗真菌药物的 TDM 提供了一系列建议。
相似文献
1
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.
2
Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation.
Clin Microbiol Infect. 2020 Nov;26(11):1481-1487. doi: 10.1016/j.cmi.2020.05.037. Epub 2020 Jun 11.
3
[Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].
Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):391-404. doi: 10.1684/abc.2014.0968.
4
Therapeutic drug monitoring for triazoles.
Curr Opin Infect Dis. 2008 Dec;21(6):580-6. doi: 10.1097/QCO.0b013e3283184611.
5
Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.
Pharmacotherapy. 2023 Oct;43(10):1043-1050. doi: 10.1002/phar.2850. Epub 2023 Aug 14.
6
Therapeutic drug monitoring of azole antifungal agents.
J Infect Chemother. 2025 Feb;31(2):102535. doi: 10.1016/j.jiac.2024.10.003. Epub 2024 Oct 5.
7
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):911-26. doi: 10.1517/17425255.2013.794785. Epub 2013 May 6.
8
Current concepts in antifungal pharmacology.
Mayo Clin Proc. 2011 Aug;86(8):805-17. doi: 10.4065/mcp.2011.0247.
9
[Clinical indications for therapeutic drug monitoring of antifungal agents. In the way for optimizing the treatment of fungal infection].
Rev Esp Quimioter. 2014 Mar;27(1):1-16.
10
Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.
Intern Med J. 2008 Jun;38(6b):521-37. doi: 10.1111/j.1445-5994.2008.01726.x.
引用本文的文献
1
Late-Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T-Cell Therapy.
EJHaem. 2025 Sep 2;6(5):e70138. doi: 10.1002/jha2.70138. eCollection 2025 Oct.
2
Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study.
Front Pharmacol. 2025 Aug 15;16:1654671. doi: 10.3389/fphar.2025.1654671. eCollection 2025.
3
Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Cardiovasc Toxicol. 2025 Aug 6. doi: 10.1007/s12012-025-10051-1.
4
Successful Treatment of Mucormycosis and Azole-Resistant Coinfection in a Diabetic Patient: A Case Report.
Infect Drug Resist. 2025 Jul 25;18:3689-3694. doi: 10.2147/IDR.S530615. eCollection 2025.
5
Necrotizing orbital infections: A comprehensive review.
Saudi J Ophthalmol. 2025 Jun 25;39(2):128-140. doi: 10.4103/sjopt.sjopt_87_25. eCollection 2025 Apr-Jun.
6
Voriconazole versus isavuconazole for invasive aspergillosis: a retrospective analysis in a medically insured U.S. population (2017-2020).
Ther Adv Infect Dis. 2025 Jun 27;12:20499361251347778. doi: 10.1177/20499361251347778. eCollection 2025 Jan-Dec.
7
Optimization of Isavuconazole Dosing in Patients with Invasive Fungal Infections Through Therapeutic Drug Monitoring: Real-World Clinical Practice Experience.
Life (Basel). 2025 Jun 12;15(6):946. doi: 10.3390/life15060946.
8
Medical Potential of Insect Symbionts.
Insects. 2025 Apr 26;16(5):457. doi: 10.3390/insects16050457.
9
Rapid Therapeutic Drug Monitoring of Voriconazole Based on High-Performance Liquid Chromatography: A Single-Center Pilot Study in Outpatients.
Antibiotics (Basel). 2025 May 8;14(5):474. doi: 10.3390/antibiotics14050474.
10
Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review.
J Fungi (Basel). 2025 May 6;11(5):362. doi: 10.3390/jof11050362.
本文引用的文献
1
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):911-26. doi: 10.1517/17425255.2013.794785. Epub 2013 May 6.
2
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67. doi: 10.1111/1469-0691.12041.
3
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population.
Ther Drug Monit. 2012 Oct;34(5):604-6. doi: 10.1097/FTD.0b013e31826a701e.
4
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Antimicrob Agents Chemother. 2012 Nov;56(11):5503-10. doi: 10.1128/AAC.00802-12. Epub 2012 Aug 13.
5
Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease.
Antimicrob Agents Chemother. 2012 Oct;56(10):5247-52. doi: 10.1128/AAC.00815-12. Epub 2012 Jul 30.
6
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.
7
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2012 Oct;56(10):5180-5. doi: 10.1128/AAC.01111-12. Epub 2012 Jul 23.
8
The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Clin Infect Dis. 2012 Oct;55(8):1080-7. doi: 10.1093/cid/cis599. Epub 2012 Jul 3.
9
Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
Antimicrob Agents Chemother. 2012 Sep;56(9):4793-9. doi: 10.1128/AAC.00626-12. Epub 2012 Jul 2.
10
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201. doi: 10.1128/AAC.00222-12. Epub 2012 May 21.
Zotero 插件